Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

Argenx's study flop in Sjögren's overshadows a win in celiac disease

Argenx on Thursday reported one success and one setback in its autoimmune disease pipeline, sending its shares tumbling. The Belgian-Dutch pharma said it is shuttering a Phase 3 trial of its ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Sources: endpoints.news · statnews.com · biopharmadive.com

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at endpoints.news →

Report a problem with this story

More in Health & Medicine

More from Thursday 8 October →